-Positive Efficacy Results Suggest the Possibility for Individualized Treatment-
-Superior Immunogenicity Profile Demonstrated-
Report is Available for Download at: www.lifesciadvisors.com/clients/ablynx
Last week, Ablynx NV (Euronext Brussels: ABLX), presented positive results of the Phase 2 open-label extension (OLE) study of ozoralizumab in patients with rheumatoid arthritis. The efficacy results were comparable to other TNFα drugs and the secondary measures were quite compelling as they suggest several advantages over TNFα blockers, including the $8.2B RA blockbuster, Humira.
Previously, Ablynx’ ozoralizumab (ATN-103) achieved proof of concept and met the primary endpoint in a Phase 2 study with 72% (p=0.006) and 37% (p=0.047) of subjects achieving an ACR20 and ACR50 response at the 80mg Q4W dose after 16 weeks, respectively. On Monday June 25, Ablynx reported positive results from 85% (n=266) of the subjects that were enrolled in the previous two studies.
